超越分子结构:比较澳大利亚和欧洲对纳米识别和分类的监管方法
Sarah Wilson1, Stephen Northey1, Rachael Wakefield-Rann1
1Institute for Sustainable Futures, University of Technology Sydney, Level 10, UTS Building 10, 235 Jones Street, Ultimo, NSW, 2007, Australia.
Regulatory toxicology and pharmacology : RTP
|September 26, 2025
概括
对纳米材料的监管框架有很大的差异. 欧洲化学品注册,评估,授权和限制法 (REACH) 使用多因素方法,而澳大利亚则采用多因素方法.
科学领域:
- 监管科学是一种监管科学.
- 纳米毒理学研究
- 化学法规 化学法规 化学法规
背景情况:
- 纳米材料在监管和毒理学中挑战了传统的物质识别和风险评估.
- 监管框架决定了如何评估新的和现有的物质,影响了风险管理策略.
研究的目的:
- 为了比较澳大利亚工业化学品引入计划 (AICIS) 和欧洲化学品注册,评估,授权和限制 (REACH) 如何将纳米毒理学纳入物质识别中.
- 探索不同纳米识别框架对监管方法和风险评估的影响.
主要方法:
- 在AICIS和REACH中对物质识别要求进行比较法律分析.
- 检查如何不断发展的纳米毒理学科学被整合到监管框架.
- 分析两个方案在纳米识别中使用的因素和特异性.
主要成果:
- REACH采用了一种全面的多因素方法,与纳米毒理学原理相一致,用于纳米识别.
- AICIS依赖于基于结构的更广泛的CAS标识符来识别物质,其特异性不同.
- 通过REACH和AICIS进行纳米识别的对比方法会导致潜在的监管数据差异.
结论:
- 在REACH和AICIS之间纳米识别框架的差异可能导致澳大利亚纳米风险监管管理的漏洞.
- 纳米材料等复杂材料的有效监管需要强大的法律信息系统,将科学知识与监管行动联系起来.
- 法律信息系统的设计对于调解化学品管理领域的科学进展和监管实践至关重要.
更多相关视频
相关概念视频
Methods of Classification and Identification
1.0K
Bacterial identification relies on a diverse array of techniques to classify and understand microorganisms, each tailored to uncover specific characteristics. Traditional morphological approaches, while still valuable, are limited for closely related or structurally simple organisms. Modern methods integrate biochemical, serological, genetic, and advanced molecular tools to achieve greater accuracy.Morphological and Biochemical TechniquesMorphological characteristics, such as cell shape and...
1.0K
Modern Molecular Taxonomy
590
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
590
Drug Nomenclature
3.2K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.2K


